{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/993 (Done on website).pdf"}, "page_content": "US 2023/0024341 Al\n\n-continued\n\nfe) rt\n\n;\n\n\\ CNV 2 \\ fe) oO fo) \u4e86 N -\u4e00 \u4e00 / \u516d fo) fo) oo HN > ; HBN byo O\n\n\u570b\n\nand\n\n7\n\nFormula\n\nII(b)\n\nFormula\n\nII(e)\n\nFormula\n\nIICd)\n\nJan. 26, 2023\n\nUS 2023/0024341 Al\n\n[0084] An embodiment of the present invention relates to a pharmaceutical composition containing a platinum(IV) complex; or a platinum(IV) complex as described herein. The pharmaceutical composition may further contain an ingredient selected from the group of, for example, an additional anti-cancer agent, an adjuvant, an antibody, a binder, a buffer, a diluent, a filler, a pharmaceutically- acceptable carrier, a preservative, a surfactant, a contrast media, a radioactive agent, a photodynamic therapy agent, a photothermal therapy agent, an ultrasonic therapy agent, and a combination thereof; or an additional anti-cancer agent, an antibody, an adjuvant, a buffer, a pharmaceutically-accept- able carrier, and a combination thereof, or an antibody, a pharmaceutically-acceptable carrier and a combination thereof, as well as other pharmaceutical components known in the art.\n\n[0085] In an embodiment herein, the antibody, peptide, and specifical tumor/bacteria targeting groups useful herein may, for example, linked to the platinum(IV) complex herein and may also be targeted against the cancer, tumor, or infection/bacteria. Thus, it is believed that the platinum(IV) complex herein will be drawn to and/or concentrated at the location of the cancer, tumor and/or infection, so as to enhance its effectiveness during use.", "type": "Document"}}